DR-242 Measuring the evolutionary dynamics of positive and negative selection in metastatic cancers
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-242 Measuring the evolutionary dynamics of positive and negative selection in metastatic cancers
In this project we aim at combining mathematical modelling of tumour evolution with cancer genomic data to measure fundamental evolutionary …
DR-241 OPTN expression in Triple negative breast cancer
Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat due to its aggressive characteristics and low …
DR-239 The causes and consequences of structural variations in cancer
Structural variations (SVs) are large scale changes of DNA, which include deletions, duplications, inversion, translocations and other more complex forms. …
DR-237 A computational framework for precision medicine of hereditary melanoma cancer
The overall objective of our study is to assess if melanoma with a specific DNA mutation (in the CDKN2A gene) …
DR-235 Exploring focal amplifications across cancers
Cells may grow more quickly when a specific subset of genes called oncogenes are activated. Normally, two DNA copies. each …
DR-231 Genome specificity of Mutagenesis
HER2-positive breast cancer is an aggressive subtype driven by amplification of the Her2/Erbb2 gene. This oncogene is amplified and implicated …
DR-230 The impact of genomic alterations in breast cancer pathogenesis
HER2-positive breast cancer is an aggressive subtype driven by amplification of the Her2/Erbb2 gene. This oncogene is amplified and implicated …
DR-223 Identification of Mutations in Signaling Proteins in Metastatic Breast Cancer Cells
Cancer-related signaling pathways frequently involve protein kinase C (PKC), a prominent enzyme that phosphorylates alpha-tubulin, a building block of microtubules. …
DR-218 Large-scale analysis of non-coding alterations in endocrine therapy resistance of breast cancer
Breast cancer is the second leading cause of cancer-related death in women worldwide. Hormone therapy has been proven effective to …
DR-215 Interplay between drug treatment and rearrangment occurrence
Cancer is driven by mutations in the genome. Several drugs, including some of the most widely used compound types, induce …
DR-204 Drivers of therapy resistance in cancer of the head and neck
Head and neck cancer can be cured in approximately half of patients suitable for radical treatment with radiotherapy. Treatment failures …
DR-185 A human interpreter validation on results generated by artificial intelligence (AI) algorithms developed for outcome and response predictions for CRC and melanoma patients: optimal use and validation of multi-layer research data
We want to achieve better care for patients with CRC and melanoma, by allowing a multidisciplinary team of researchers to …
We willen het maximum aan informatie uit de tumor van de patiënt halen. Deze DNA-test is daarvoor het best beschikbare instrument. Er is maar één keer weefsel, een biopt, met voldoende tumorcellen nodig. Omdat het hele genoom wordt onderzocht, ook de gebieden in het DNA waarvan we nu nog niet weten of de gevonden afwijkingen belangrijk zijn, is deze DNA-test tumortype onafhankelijk en toekomstbestendig. Deze eigenschappen zijn de twee belangrijkste eigenschappen van WGS.